The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...
It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...
The general mood among these heavyweight investors is divided, with 57% leaning bullish and 26% bearish. Among these notable ...
Viking Therapeutics, Inc. (VKTX) closed at $67.10 in the latest trading session, marking a +0.55% move from the prior day.
Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $66.73 which represents a slight increase of $3.92 or 6.24% from the prior close of $62.81. The stock opened at $63.08 and ...
iTeos Therapeutics shares dipped 13.7% to $14.40 in pre-market trading. Here are some big stocks recording losses in today's ...
In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...
2d
In a report released yesterday, Justin Zelin from BTIG maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a ...
Whereas Viking Therapeutics saw its shares fly due to favorable phase 2 trial results with its lead candidate, Terns is ...
Jim Cramer is probably the closest thing we have to stock market superstar influencer. The host of CNBC’s “Mad Money” show is ...
Interview with the Milanese immunologist Attilio Speciani. They call it an anti-obesity drug, but it's not just that: in ...
In the,Healthcare sector,, clinical trials are pivotal in determining the success of new treatments. Viking Therapeutics, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback